Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels

Alex, J.; Flores, Raja M.; Mathew, Anu; Gonzalez-Espinoza, Rita; Bott, Matthew; Ladanyi, Marc; Rusch, Valerie W.; Fleisher, Martin

doi:10.1515/cclm.2010.066

Cited by 33 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other authors confirmed OPN as an effective marker for MPM diagnosis (22,(25)(26)(27)(28) and the utility as biological markers for the health surveillance of past-exposed patients (28). Nevertheless, further studies with a larger sample size and better design are needed to carefully assess the diagnostic power of this biomarker (25).…”

Section: Osteopontin (Opn)mentioning

confidence: 84%

Serum mesothelin and other biomarkers: what have we learned in the last decade?

et al. 2018

View full text Add to dashboard Cite

In the last decade there is been much interest in noninvasive, economic and well-accepted diagnostic tests for screening of subjects exposed to asbestos, and in patients with malignant pleuric mesothelioma (MPM) for diagnosis or monitoring response to treatment. Several biomarkers have been suggested as tools for screening and early diagnosis of MPM. Currently, in patients with MPM, have been reported high levels of soluble mesothelin-related peptides (SMRP), plasmatic osteopontin (pOPN), vimentin, fibulin-3 and many others as promising marker for diagnosis, even their use in prevention monitoring is still discussed. In this type of disease, a key role could be played by miRNAs, which expression has been investigated in a large series of MPM to examine new pathways useful in diagnosis, prognosis and therapy. An altered expression of some proteins has been reported, useful as biomarkers, in comparative proteomic analysis of malignant pleural mesothelioma. New promising markers are nowadays under study and alone or better in combination, they'll be very helpful in diagnosing, monitoring mesothelioma patients or for screening of risk groups.

show abstract

Section: Osteopontin (Opn)mentioning

confidence: 84%

Serum mesothelin and other biomarkers: what have we learned in the last decade?

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, the specific role of OPN in the pathogenesis of MPM still remains unclear. Unlike SMRP and MPF, OPN concentrations do not show any consistent directional change in post-surgical samples [21,40], suggesting no connection with tumor bulk. It was observed in an analysis of 91 patients that serum OPN assayed by ELISA with a 350-ng/mL cutoff remained as a negative prognostic factor for patients' survival in the univariate and multivariate model, which could be explained by the role of elevated OPN level in stimulating tumor growth and spread [23].…”

Section: Opnmentioning

confidence: 86%

Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma

Liu

Jiao

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor of the pleura closely related to asbestos exposure. Rare as it is, the incidence of MPM is predicted to increase mainly as a result of a lengthy latency period from the initial asbestos exposure, making it a public health concern for the next decades. Moreover, the patients with MPM have an extremely poor prognosis due to its high resistance to conventional oncologic treatments and delayed diagnosis. Although the result of current therapeutic modalities based on patient features and clinical stages is very frustrating, great advances have been shown in the knowledge of molecular biology of MPM in recent years. This is accompanied by dozens of putative prognostic biomarkers that are actively involved in tumor biological activities. These prognostic candidates can offer us a new insight into the biological characteristics of MPM, contributing to development of individualized therapeutic strategies directed against oncogenesis and tumor progression. Thus, personalized approaches based on the molecular biology of the patient's tissue or body fluid will potentially improve the present disappointing outcome, bringing new hope for patients with MPM. This article reviews the principal and several novel biomarkers that can have an influence on prognosis, in the hope that they can provide us with a more profound understanding of the biology of this lethal disease.

show abstract

“…These findings are consistent with those first reported by Robinson et al (36), suggesting that the use of serum SMRP levels for diagnosing MM has excellent universality and reproducibility. Based on previous studies, including our own, SMRP is considered to be a highly specific biomarker for MM; however, its sensitivity, ranging from 48-80%, is moderate (9,(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(27)(28)(29)(30)(31)(32)(33)(34)(35). To improve the performance of SMRP in diagnosing MM, there is a need to increase the sensitivity while maintaining a high degree of specificity.…”

Section: Discussionmentioning

confidence: 99%

“…Together with the advances in imaging studies and endoscopic examinations, the development of biomarkers useful for serum or effusion diagnosis is crucial for the early diagnosis of MM. Currently known biomarkers for diagnosing MM include cytokeratin 19 fragment (CYFRA) (5-7), tissue polypeptide antigen (TPA) (5,6,8), hyaluronic acid (8), carbohydrate antigen (CA125) (8,9) and osteopontin (10)(11)(12)(13)(14)(15). However, these markers have low specificity for MM.…”

Section: Introductionmentioning

confidence: 99%

Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma

Fukuoka

Kuribayashi

Yamada

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Malignant mesothelioma (MM) is a highly aggressive tumor associated with asbestos exposure. The identification of a marker specific for MM may be of considerable value for the early detection of this tumor and may be used in particular to screen groups with a history of asbestos exposure. The aim of this study was to evaluate serum soluble mesothelin-related peptide (SMRP) levels as a diagnostic marker for MM and investigate whether its diagnostic value is enhanced by combination with other biomarkers. Serum SMRP levels were measured using a quantitative enzyme-linked immunosorbent assay in 96 patients with MM, 55 patients with lung cancer and 39 individuals with a history of asbestos exposure. Receiver operating characteristic curves were constructed for performance evaluation. Stepwise logistic regression analysis was used to select marker combinations (MCs). Serum SMRP levels in patients with MM were significantly higher compared to those in the other groups (P<0.001). The sensitivity of SMRP levels in diagnosing MM was 56% and its specificity for MM vs. lung cancer and individuals with asbestos exposure was 87 and 92%, respectively. The area under the curve (AUC) was 0.76 [95% confidence interval (CI): 0.68-0.83] for the differentiation between MM and lung cancer and 0.78 (95% CI: 0.71-0.86) for the differentiation between MM and individuals with asbestos exposure. For the MC of presence of effusion, SMRP and carcinoembryonic antigen (CEA) levels, the AUC for the differentiation between MM and lung cancer (0.92; 95% CI: 0.88-0.97) and the differentiation between MM and individuals with asbestos exposure (0.93; 95% CI: 0.87-1.0) was significantly higher compared to that for SMRP alone (P= 0.0001 and 0.0058, respectively). While the specificity of this MC was comparable to SMRP alone, its sensitivity was ~20% higher compared to that of SMRP alone. Therefore, combining SMRP and CEA improves the diagnostic performance of SMRP alone. A combination of serum biomarkers, including SMRP, may facilitate the non-invasive diagnosis of MM. IntroductionMalignant mesothelioma (MM) is a tumor that develops from the serous membranes that line the body cavities and it may arise in the pleura, peritoneum and pericardium; in addition, although extremely rare, it may also develop in the tunica vaginalis testis. The most common form of this disease is the malignant pleural mesothelioma (MPM). MM was previously considered as being extremely rare; however, its incidence and associated mortality rate exhibited a sharp increase worldwide over the last 50 years, due to the close association of MM with asbestos exposure. The prognosis of MPM is poor, with a median survival of ~9-17 months (1). However, in selected patients with epithelioid tumor histology, early-stage disease, who undergo trimodality treatment (combination of chemotherapy, postoperative radiotherapy and extrapleural pneumonectomy), median overall survival of 51 months and 5-year survival rates of 46% have been reported (2). Recent phase II trials reported a m...

show abstract

Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels

Cited by 33 publications

References 33 publications

Serum mesothelin and other biomarkers: what have we learned in the last decade?

Serum mesothelin and other biomarkers: what have we learned in the last decade?

Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma

Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma

Contact Info

Product

Resources

About